Neurocrine Biosciences
NBIX
#1633
Rank
NZ$16.89 B
Marketcap
$170.81
Share price
1.28%
Change (1 day)
-24.19%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $3.22

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.30. In 2022 the company made an earnings per share (EPS) of $2.71 an increase over its 2021 EPS that were of $1.60.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$3.2218.79%
2022$2.7169.47%
2021$1.60-78.21%
2020$7.35990%
2019$0.6781.82%
2018$0.37-113.5%
2017-$2.750.62%
2016-$2.7357.28%
2015-$1.7425.61%
2014-$1.3818.84%
2013-$1.16-1085.71%
2012$0.12-89.71%
2011$1.15-500%
2010-$0.29-86.92%
2009-$2.19-43.48%
2008-$3.88-57.8%
2007-$9.1892.58%
2006-$4.77371.67%
2005-$1.01-52.76%
2004-$2.1436.56%
2003-$1.57-70%
2002-$5.22118.31%
2001-$2.398.4%
2000-$2.2148.86%
1999-$1.48-20%
1998-$1.85-479.31%
1997$0.49

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.52 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.93-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.99-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$9.15 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.20 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.13-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.79-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$5.10-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA